Klugman garp sa part3 0

http://www.cdc.gov/ncidod/dhqp/pdf/ar/mdroGuideline2006.pdf

Clin Infect Dis 2007 (Jan 15); 44: 159-77

Hospital Infections in Developing Countries Hardly on the radar screen  Need assessments are urgent  Disease burden likely to be enormous  An urgent priority underserved area for GF 

24

What is the Capacity to Detect Resistance in Developing Countries ?

ď Ž

Almost nil

25

The Development of a Global Awareness of the Importance of Laboratory Capacity IHR  GLI  Pepfar (ASM)  WHO Lab Capacity Meeting Lyon, 2008  WHO Antimicrobial Resistance Meetings, Geneva, 2009 

26

ASM Lab Cap Countries Mediterranean Sea

TUNISIA MOROCCO

ALGERIA

WESTERN

LIBERIA

EGYPT

NIGER

CHINA

BENIN TOGO

COTE

ERITREA

CHAD

BURKINA

GUINEA

SIERRA LEONE

GUATEMALA

MAL I

SENEGAL

GUINEA BISSAU

LIBYA

Red Sea

MAURITANIA

THE GAMBIA

INDIA

NIGERIA CAMEROON

EQUATORIAL GUINEA

GABON

REP. OF THE CONGO

UGANDA

DEMOCRATIC REPUBLIC OF THE CONGO

KENYA

BURUNDI

Ocean

TANZANIA

ANGOLA

SOMALIA

Indian

RWANDA

(ZAIRE)

South

ETHIOPIA

CENTRAL AFRICAN REPUBLIC

GHANA

D’IVOIRE

DJIBOUTI

SUDAN

Atlantic Ocean

HAITI

ANGOLA

MALAWI

ZAMBIA ZIMBABWE

NAMIBIA SOUTH AFRICA Walvis Bay

MOZAMBIQUE

BOTSWANA LESOTHO

SOUTH AFRICA

SWAZILAND

Indian Ocean

MADAGASCAR

THAILAND

Conclusion Resistance is biologically inevitable and its magnitude is proportional to the access of the organism to the antimicrobial. ď Ž Increasing access to care will increase resistance. ď Ž Developing countries are at great risk given their lack of capacity to detect resistance and to control its ascent. ď Ž

28